Test Catalog


Subclinical Hypothyroidism:

An Update for Primary Care Physicians

March 2009

Subclinical hypothyroidism (SCH) is defined as a serum thyroid-stimulating hormone (TSH) level above the upper limit of normal despite normal levels of serum free thyroxine. Serum TSH has a log-linear relationship with circulating thyroid hormone levels (a 2-fold change in free thyroxine will produce a 100-fold change in TSH). Thus, serum TSH measurement is the necessary test for diagnosis of mild thyroid failure when the peripheral thyroid hormone levels are within normal laboratory range. The individual range for peripheral thyroid hormones is narrower than the population reference laboratory range; therefore, a slight reduction within the normal range will result in elevation of serum TSH above the normal range.

Subclinical hypothyroidism or mild thyroid failure is a common problem, with a prevalence of 3% to 8% in the population without known thyroid disease. The prevalence increases with age and is higher in women. After the sixth decade of life, the prevalence in men approaches that of women, with a combined prevalence of 10%. Antithyroid antibodies can be detected in 80% of patients with SCH, and 80% of patients with SCH have a serum TSH of less than 10 mIU/L.

Before diagnosis of SCH, other causes of an elevated TSH level, such as recovery from nonthyroidal illness, assay variability, presence of heterophile antibodies interfering with the TSH assay, and certain cases of central hypothyroidism with biologically inactive TSH and thyroid hormone resistance, should be excluded. However, the most common cause of elevated TSH is autoimmune thyroid disease. Previous radioiodine therapy, thyroid surgery, and external radiation therapy can also result in mild thyroid failure. Transient SCH may occur after episodes of postpartum, silent, and granulomatous thyroiditis.

The clinical importance of and therapy for mild elevation of serum TSH (<10 mIU/L) and the exact upper limit of normal for the serum TSH level remain subjects of debate. When the TSH level is above 10 mIU/L, levothyroxine therapy is generally agreed to be appropriate. However, management of patients with a serum TSH level of less than 10 mIU/L is controversial. Some authors argue for routine and some for selective therapy. A recent 2007 meta-analysis of 14 randomized clinical trials enrolling a total of 350 patients concluded that levothyroxine replacement therapy for SCH does not result in improved survival or decreased cardiovascular morbidity. Data on health-related quality of life and symptoms did not show significant differences between intervention groups. Some evidence indicates that levothyroxine replacement improves some parameters of lipid profiles and left ventricular function.

What is the upper limit of normal for the serum TSH level?

Lowering the upper limit of normal for the serum TSH level from 5.0 to 3.0 or even 2.5 mIU/L has been proposed, but such proposals have been met with substantial critique. The strongest argument in favor of lowering the upper limit of normal for the serum TSH level is the higher level of antithyroid antibodies detected in persons with a serum TSH level between 3.0 and 5.0 mIU/L and the higher rate of progression to clinical thyroid disease. After exclusion of persons with goiter, antithyroid antibodies, and a family history of thyroid disease, the mean serum TSH is 1.5 mIU/L. The serum TSH distribution curve is not Gaussian; there is a tail end at the upper limits of normal. If the distribution is extrapolated to be Gaussian, then the upper limit for the 97.5th percentile will be 2.5 mIU/L. The argument against lowering the upper limit of normal for TSH values is that 22 to 28 million more Americans would be diagnosed with hypothyroidism without any clinical or therapeutic benefit from this diagnosis. Our own data also show that decreasing the upper limit of the TSH reference range to 3.0 mIU/L results in more than a 4-fold increase in diagnosis of hypothyroidism among patients without history of thyroid disease seen in a tertiary medical center. No clear evidence supports a benefit for intervening at these levels of TSH. In contrast, lowering of the level of TSH from the upper limit of normal to lower normal range by adjustment of levothyroxine dose does not improve sense of well-being and nonspecific complaints. Recent reanalysis of the data from the National Health and Nutrition Examination Survey III study has suggested that serum TSH distribution progressively shifts toward higher concentrations with age and that the prevalence of SCH may be significantly overestimated in older age groups unless an age-specific range for TSH is used. In a recent study of 766 persons with negative findings on antithyroid antibody assay, normal findings on thyroid ultrasonography, and no evidence of thyroid disease, Hamilton et al determined a serum TSH level of 4.1 mIU/L to be the upper reference limit. This value is more compatible with clinical experience and is a reasonable compromise.

Although persons with a TSH level between 3.0 and 5.0 mIU/L are more likely to have positive antithyroid antibodies and future thyroid disease, the lack of evidence for a benefit from levothyroxine therapy at these levels makes keeping the upper limit of TSH at 4.0 to 5.0 (depending on the laboratory) more reasonable. For persons older than 70 years, values up to 6.0 or even 7.0 mIU/L in the absence of antithyroid antibodies should not result in diagnosis of hypothyroidism. Regardless of the chosen upper limit of normal, a convincing argument can be made for closer follow-up of persons with a TSH level of 3 to 5 mIU/L, in particular if antithyroid antibodies are detected.

Different normal TSH values are proposed for pregnancy. The range of serum TSH levels in the first trimester of pregnancy is 0.03 to 2.3 mIU/L; the upper limit of normal is 3.5 mIU/L in both the second and third trimesters of pregnancy.

Screening for SCH

Uniform national guidelines for screening for thyroid disease with serum TSH levels have not been established. However, because of the high prevalence of SCH and associated metabolic risk factors such as hyperlipidemia, the American Thyroid Association recommends screening by measurement of serum TSH beginning at age 35 years and every 5 years thereafter. The evidence in favor of screening is particularly compelling in women, but it can also be justified for men as a relatively cost-effective measure in the context of the periodic health examination. Persons with symptoms and signs potentially attributable to thyroid dysfunction and those with risk factors for its development may require more frequent serum TSH testing. The American College of Physicians acknowledges that treatment for subclinical thyroid dysfunction is controversial but suggests that screening to detect thyroid dysfunction may be indicated in women older than 50 years. Because of potential implications of SCH for adverse outcome of pregnancy and neuropsychiatric development of the fetus, aggressive case finding in pregnant women or in women anticipating pregnancy has been suggested. However, relying only on aggressive case finding results is missing a third of women with overt hypothyroidism or SCH.

Before recommending routine screening of the general population, large-scale randomized trials are needed to prove that treatment will improve quality of life in otherwise healthy patients who have the mildly elevated TSH level (5–10 mIU/L) typical of most SCH cases. Meanwhile, clinicians should have a low threshold for obtaining a serum TSH level in women who have vague suggestive symptoms, who are pregnant or anticipating becoming pregnant, or who have a strong family history of autoimmune thyroid disease. Many thyroidologists advocate routine screening before and during pregnancy.

Proposed adverse consequences of SCH

Although studies have pointed to some adverse effects of SCH, no consensus exists as to the clinical importance of the adverse effects and the benefits of levothyroxine therapy, particularly for the 80% of patients with SCH who have a TSH of less than 10 mIU/L, because of the different levels of TSH and degrees of thyroid dysfunction in these studies (Table 1). A discussion of some of the proposed adverse effects of SCH follows.

Clinical condition
Strength of
Benefits of
Progression to overt
Adverse cardiac end points
No evidence
Elevation in serum total
cholesterol and LDL-C levels
Cardiac dysfunction
Systemic hypothyroid
No clear
Psychiatric symptoms
No clear

TABLE 1. Quality of Evidence on the Strength of Association and Risks/Benefits of Levothyroxine Treatment of Subclinical Hypothyroidism for Patients With a Serum TSH Level of 4.5 to 10.0 mIU/La
a LDL-C = low-density lipoprotein cholesterol; TSH = thyroid-stimulating hormone.
b Thyroid hormone therapy normalizes the serum TSH level at any TSH concentration. Overt hypothyroidism occurs earlier in untreated patients with a serum TSH level of >10 mIU/L than in those with a serum TSH level of 4.5 to 10.0 mIU/L.
c Available data do not distinguish between serum TSH concentrations of 4.5 to 10 mIU/L and of more than 10 mIU/L.
Adapted from JAMA, with permission of the American Medical Association. Copyright © 2004. All rights reserved.

Progression to overt hypothyroidism

Patients with SCH have a high rate of progression to clinically overt hypothyroidism, 2.6% each year if thyroperoxidase (TPO) antibodies are absent and 4.3% if they are present. However, some persons do not show progression and some experience normalization. A TSH level greater than 10 mIU/L predicts a higher rate of progression, and a level of less than 6 mIU/L predicts a lower likelihood of progression. In a study in men and women older than 55 years with a mean follow-up of 32 months, the TSH level normalized in 52% of those with a serum TSH of less than 10 mIU/L.

Systemic symptoms of hypothyroidism

Several randomized studies of the effect of levothyroxine therapy in patients with SCH are available. One study limited to patients with serum TSH levels from 5 to 10 mIU/L did not show any benefit. Some studies (range in TSH level, 3-32 mIU/L) showed improved symptom scores or improved memory in a quarter of patients. Many recent studies have not shown improvement in mood, anxiety, and cognition in older persons. In a previous scientific review in 2004, available data were considered insufficient to support a benefit for levothyroxine therapy in patients with SCH, in particular for the group with TSH less than 10 mIU/L, and a similar conclusion can again be drawn in 2008.

Lipid abnormalities and other cardiac risk factors

The Colorado Health Fair study showed that the mean total cholesterol level was 216 mg/dL (to convert to mmol/L, multiply by 0.0259) for euthyroid patients and 224 mg/dL for patients with SCH. Several randomized studies have shown reduction of low-density lipoprotein cholesterol by levothyroxine therapy. However, most of the studies showing benefit are not categorized for serum TSH levels of 5.0 to 10.0 mIU/L. A meta-analysis of 13 studies concluded that the lipid profile improved with therapy. In a 2004 review, data were considered insufficient to show benefits of levothyroxine therapy on lipid levels. In my estimation, the possibility that lipid levels will improve with levothyroxine therapy is fair if the serum TSH level is greater than 10 mIU/L and questionable if the TSH level is less than 10 mIU/L.

In a large population-based study, emerging risk factors such as elevated C-reactive protein, homocysteines and lipoprotein(a) levels were not found to have a role in SCH. Improvement of endothelial dysfunction and insulin resistance after levothyroxine therapy has been suggested. In the absence of large-scale randomized trials, evidence remains inconclusive.

Adverse cardiac end points

The cross-sectional Rotterdam Study showed an association of SCH with myocardial infarction and aortic calcification. In contrast, the Wickham study showed no increased cardiac mortality in a 20-year follow-up. A more recent observational study also did not show any association between unrecognized SCH and cardiovascular events or mortality. However, several more recent meta-analyses of observational studies found an association between SCH and coronary artery disease. The risk is lower when higher-quality studies are pooled. A recent analysis of 7 cohort studies concluded that the relative risk of all-cause mortality was increased compared with euthyroid controls, particularly in patients with comorbid conditions. Another meta-analysis of 15 studies showed an increased prevalence and incidence of cardiovascular mortality only in a relatively younger population. Taken together, the findings of these 6 recent meta-analyses suggest that a cardiovascular risk exists for persons younger than age 70 years with no effect for those aged 70 to 80 years and a possibly protective effect for those older than 80 years. Thus, the cardiovascular risk issue remains controversial, and large-scale, government-sponsored, multicenter, randomized, placebo-controlled studies are needed to assess the efficacy of levothyroxine therapy in risk reduction.

Cardiac dysfunction

Studies have shown slowed left ventricular relaxation time, increased vascular tone at rest, and left ventricular systolic dysfunction with exercise and impaired endothelial function. Some studies have shown improvement of cardiac contractibility and systolic time interval with levothyroxine therapy. No evidence exists to support an association between heart failure and a serum TSH level of less than 10.0 mIU/L. Again, most studies were not categorized for degrees of TSH elevation, and data remain insufficient for a TSH level less than 10 mIU/L but strongly suggestive for a TSH level greater than 10 mIU/L.

Adverse fetal effects

A seminal study by Haddow et al showed a 7-point reduction in intelligence quotient in children aged 7 to 9 years whose mothers had SCH at pregnancy compared with the children of euthyroid mothers. Although this was a single study, it nevertheless points to the need for screening of pregnant women and therapy for mild thyroid failure in women who are pregnant or planning on becoming pregnant.

Neuromuscular dysfunction

It has been suggested that neuromuscular symptoms and dysfunction are common in patients with SCH and can be reversed by levothyroxine treatment. A definitive answer will require more studies with TSH levels stratified as less than or greater than 10 mIU/L.

Psychiatric and cognitive dysfunction

Data related to aggravation of depression, bipolar disorder, and effect on cognitive function have been presented. A recent study showed no association with anxiety, depression, or cognitive dysfunction. Nonetheless, it is still reasonable to have a low threshold for therapy for SCH in patients with depression, bipolar disorder, and cognitive dysfunction.

Management of SCH

Management of SCH differs depending on whether the serum TSH concentration is 3 to 5 mIU/L, 5.1 to 10 mIU/L, or higher than 10 mIU/L.

Serum TSH concentration of 3 To 5 mIU/L

Lowering the upper limit of normal for the serum TSH level from 5.0 to 3.0 mIU/L is still controversial. Levels between 3 and 5 mIU/L are unlikely to indicate a clinically important abnormality, and levothyroxine therapy at these levels may or may not provide a benefit. Although persons with a serum TSH level of 3 to 5 mIU/L may be at higher risk of progression to hypothyroidism, no firm evidence of health consequences exists. In fact, in a randomized, crossover, 12-week study of patients with symptoms suggestive of hypothyroidism with serum TSH in the upper normal range, no difference in cognitive and psychological function was observed between levothyroxine-treated and control groups. Given these findings, intervention cannot be recommended for this group, but follow-up by serum TSH measurement in 1 year would be a reasonable approach, particularly if antithyroid antibodies are detected.

Serum TSH concentration of 5.1 to 10 mIU/L

Large-scale randomized studies to conclusively show reduction of cholesterol with levothyroxine therapy in this subgroup are lacking. Most studies are not stratified for different categories of serum TSH levels, and although benefits for symptoms and lipid levels have been shown for mild thyroid failure as a group, results cannot be extended to most patients with SCH who are in this subgroup. One study of TSH levels of 5.0 to 10.0 mIU/L did not show any benefit. Also, cognitive, neuropsychiatric, cardiac, and muscle abnormalities described in studies including a wide spectrum of TSH levels in SCH should be confirmed by larger randomized studies. The possibility that an elevated serum TSH level is a cardiovascular risk factor is still highly controversial. Hence, decision for levothyroxine therapy for this group should be individualized and should depend on the age of the patient (favoring therapy for younger persons), associated medical conditions, degree of TSH elevation, persistence and gradual increase of TSH, presence of antithyroid antibodies, presence of goiter, and hypothyroid symptoms (Table 2).

Pregnancy or intention of pregnancy
Therapeutic trial for possible hypothyroid symptoms
Patient preference
Childhood and adolescence
2 TSH levels >8 mIU/L
Bipolar disorder, depression
Presence of antithyroid antibodies
Progressive TSH increase
Ovulatory dysfunction
Young age of the patient

TABLE 2. Factors Favoring Levothyroxine Therapy in Patients With a Thyroid-Stimulating Hormone (TSH) Level of 5 to 10 mIU/L

Given both the findings of reduced intelligence quotient in the children of women who had SCH while pregnant and the adverse effects of mild thyroid failure on pregnancy outcome, levothyroxine therapy should be advised for pregnant women and women who anticipate becoming pregnant. Because of the effect of thyroxine on growth and development, levothyroxine therapy for children and adolescents is also reasonable. Therapy may be considered for patients with a persistent serum TSH level of more than 8 mIU/L because these levels are associated with a 70% progression to a TSH level of 10 mIU/L in 4 years (V.F. and colleagues, unpublished data, 2003).

Serum TSH concentration greater than 10 mIU/L

Most thyroidologists agree that all patients with SCH and a serum TSH level above 10 mIU/L should be treated with levothyroxine. Evidence is more compelling for the adverse effects of mild thyroid failure in this group. Studies have shown that levothyroxine therapy results in an 8-mg reduction in low-density lipoprotein levels. Among the factors that predict response of lipid levels to levothyroxine therapy are higher levels of TSH, insulin resistance, higher levels of pretherapy cholesterol, and type III hyperlipidemia. Some evidence suggests that mild thyroid failure can aggravate bipolar disorder and depression and that it is associated with abnormalities of muscle function, nerve conduction, cardiac function, and cognitive and psychological function, with improvement after levothyroxine therapy.

Levothyroxine therapy for SCH

For all patients with SCH and a serum TSH concentration above 10 mIU/L and for patients with serum TSH concentrations of 5.1 to 10.0 mIU/L in whom individualized decision for therapy is made, therapy should be started with levothyroxine. We do not currently recommend a combination of T4 plus T3 therapy. In my experience, the usual required daily levothyroxine dose is 50 to 75 µg. Anticipating future progression of thyroid failure, some endocrinologists recommend a full replacement dose. I prefer to start with a daily dose of 25 to 75 µg, depending on the age of the patient, the level of free thyroxine, and the serum TSH level. Serum TSH should be checked after 8 weeks, and the dose should be adjusted. Once a normal serum TSH level has been achieved, TSH should be measured again after 6 months and then annually. In younger persons, a reasonable goal for serum TSH is 0.3 to 3.0 mIU/L. For older age groups, the therapeutic goal can be higher. The benefits of fine-tuning levothyroxine therapy to achieve lower levels of serum TSH should be weighed against the possibility of adverse effects of overzealous levothyroxine therapy resulting in suppressed TSH and SCH.


Subclinical hypothyroidism occurs in the clinical setting of a serum TSH level above the upper limit of normal despite a normal serum free thyroxine concentration. Initiating levothyroxine replacement therapy is recommended for all patients with a TSH greater than 10 mIU/L, even if the free thyroxine concentration is within normal laboratory range. However, treatment of patients with a serum TSH level between 5 and 10 mIU/L remains controversial. The strongest arguments for levothyroxine therapy are the high risk of progression to overt hypothyroidism, the possible improvement of quality of life, and the possibility that SCH is a cardiovascular risk factor. Recent evidence shows that any possible increased cardiovascular risk would be to persons younger than 70 years; those aged 70 and 80 years have no additional risk, and those older than 80 years may actually enjoy a protective benefit. Large-scale, government-sponsored, multicenter, randomized, placebo-controlled studies are urgently needed to assess the efficacy of levothyroxine therapy in the subgroup with TSH levels of less than 10 mIU/L. Meanwhile, therapy of this subgroup should be individualized by taking into account patient preference, presence of symptoms, age, and associated medical conditions.

Reprinted from Fatourechi V: Subclinical Hypothyroidism: An Update for Primary Care Physicians. Mayo Clin Proc, January 2009;84(1):65-71. References omitted. Used with permission. The complete article is available online at www.mayoclinicproceedings.org.


Back to top

Tell Us What You Think